Table 1 Characteristics of the ranibizumab and aflibercept groups
IVR (16 cases, 16 eyes) | IVA (20 cases, 20 eyes) | P-value | |
|---|---|---|---|
Age (years) | 67.8 ± 9.9 | 70.0 ± 7.1 | 0.50 |
Sex (male/female) | 8/8 | 10/10 | 0.79 |
Pre-injection visual acuity (logMAR) | 0.53 ± 0.34 | 0.40 ± 0.22 | 0.64 |
Duration from onset (months) | 2.0 ± 1.4 | 2.0 ± 1.6 | 0.50 |
Pre-injection CMT (µm) | 564.2 ± 268.5 | 542.4 ± 172.5 | 0.97 |
Pre-injection SFCT (µm) | 228.8 ± 50.1 | 246.1 ± 59.1 | 0.27 |
Major/Macula | 10/6 | 16/4 | 0.32 |
Hypertension presence/absence | 10/6 | 7/13 | 0.31 |